DGX stock: buy or sell?
November 19th, 2019
Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally.
Should I buy DGX stock?Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. That's why is so important to choose your own trading plan that matches with your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
None of our preferred buy setups matches with Quest Diagnostics stock situation right now, therefore this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Quest Diagnostics stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we detected 15 ratings published for DGX stock in the last month.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-7-24||JPMorgan Chase & Co.||n/a||Neutral|
|2019-7-24||Credit Suisse Group||n/a||Neutral|
|2019-7-15||Goldman Sachs Group||Neutral||Sell|
|2019-4-2||Jefferies Financial Group||Hold||Buy|
|2019-3-18||Credit Suisse Group||Outperform||Neutral|
|2019-2-19||Credit Suisse Group||Outperform||Outperform|
DGX stock analysis
Quest Diagnostics shares raised 0.48% to $104.48 today.
Shares of Quest Diagnostics raised a slightly good 0.48% and closed at $104.48. In the last 6 days when DGX stock price broke up the SMA100d line, it gained $2.56 (2.51%).
Shares of Quest Diagnostics ended this week at $104.48 and stayed steady a neutral 0.25%.
Observing the weekly chart, DGX marked an uptrend of rising tops and rising bottoms. Since its last top by mid September at $107.43, price slid and bounced up back from $99.57. Breaking down under $99.57 would cancel the current uptrend and it might test lower supports. Note that $107.43 might act as a resistance line. Since mid June when SMA20w and SMA40w crossed up, DGX price gained $6.14 per share (6.24%). Since price and SMA40w lines crossed up late April, DGX climbed $19.60 (23.09%).
DGX stock price history
DGX IPO was on December 17th, 1996 at $3.01 per share1. Since then, DGX stock surged a 3,371.10%, with an average of 153.20% per year. If you had invested $1,000 in DGX stock in 1996, it would worth $33,711.00 today.
1: Adjusted price after possible price splits or reverse-splits.
DGX stock historical price chart
DGX stock reached 52-week highs on September at $107.43, and all-time highs 2018-06-25 with a price of 112.17.
DGX stock price target is $104.90Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last 30 days we found 13 price targets for DGX stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-8-23||Morgan Stanley||Raises Target||$111.00||$121.00||9%|
|2019-7-24||Morgan Stanley||Raises Target||$104.00||$111.00||6.7%|
|2019-7-24||JPMorgan Chase & Co.||Raises Target||$100.00||$111.00||11%|
|2019-7-24||Credit Suisse Group||Reiterates||$99.00||$105.00||6.1%|
|2019-7-24||Canaccord Genuity||Raises Target||$108.00||$112.00||3.7%|
|2019-7-15||Goldman Sachs Group||Downgrades||$90.00||$85.00||-5.6%|
|2019-4-25||Morgan Stanley||Raises Target||$98.00||$104.00||6.1%|
|2019-4-24||UBS Group||Raises Target||$91.00||$99.00||8.8%|
|2019-3-18||Credit Suisse Group||Downgrades||n/a||$91.00||-|
|2019-2-19||Credit Suisse Group||Lowers Target||$103.00||$101.00||-1.9%|
Financials and fundamental analysis
Earnings date and Earnings per ShareAfter publishing its last earnings report on February, Quest Diagnostics . Unfortunately, reported EPS is not yet available in our database.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual sales report draw a slightly fine gain of 1.74% to $7,531.00 million dollars. Improving that, its earnings margin (compared to sales) remained steady to 9.77%, that is $736.00 million.
|2013||$7,150 M||-||$811 M11.3%||-|
|2014||$7,435 M||3.99%||$556 M7.5%||-31.44%|
|2015||$7,493 M||0.78%||$709 M9.5%||27.52%|
|2016||$7,515 M||0.29%||$645 M8.6%||-9.03%|
|2017||$7,402 M||-1.50%||$772 M10.4%||19.69%|
|2018||$7,531 M||1.74%||$736 M9.8%||-4.66%|
Quarterly financial resultsQuest Diagnostics reported $1,839.00 million in sales for 2018-Q4, a -2.65% decline compared to previous quarter. Reported quarter income marked $127.00 million with a profit margin of 6.91%. Profit margin decreased a -4.37% compared to previous quarter when profit margin was 11.28%. When comparing turnover to same quarter last year, Quest Diagnostics sales marked a spooky slide and plunged a -15.33%. Looking back to recent quarterly results, Quest Diagnostics posted 2 positive quarters in a row.
|2017-Q2||$1,940 M||-||$193 M9.9%||-|
|2017-Q3||$1,930 M||-0.52%||$160 M8.3%||-17.10%|
|2017-Q4||$2,172 M||12.54%||$254 M11.7%||58.75%|
|2018-Q1||$1,884 M||-13.26%||$177 M9.4%||-30.31%|
|2018-Q2||$1,919 M||1.86%||$219 M11.4%||23.73%|
|2018-Q3||$1,889 M||-1.56%||$213 M11.3%||-2.74%|
|2018-Q4||$1,839 M||-2.65%||$127 M6.9%||-40.38%|
|2019-Q1||$1,891 M||2.83%||$164 M8.7%||29.13%|
Quest Diagnostics ownershipWhen you are planning to invest in shares of a company, it's always worth to check its ownership structure.
Quest Diagnostics shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 0.35% of all shares.
Bearish positions for DGX stock account 0.00%, no big difference from last month.
For a better understanding, the next table shows ownership data compared to other related stocks:
|Market cap||$14.1 B||$135.5 M||$16.6 B||$2.5 B||$53.5 M|
|Total shares||134.7 M||47.6 M||97.1 M||103.9 M||5.5 M|
|Float shares||134.0 M||35.1 M||96.5 M||100.4 M||4.7 M|
|- Institutional holdings (%)||91.5%||75.8%||94.1%||77.2%||58.5%|
|- Insider holdings (%)||0.4%||7.4%||0.6%||8.1%||7.8%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Tuesday, November 19th, 2019|
|Day range||$103.77 - $104.83|
|Average true range||$1.31|
|50d mov avg||$103.43|
|100d mov avg||$102.32|
|200d mov avg||$97.07|
Quest Diagnostics performanceTo better understand Quest Diagnostics performance you must becnhmark its gains with other related stocks in same sector or industry. We compared Quest Diagnostics against Enzo Biochem, Laboratory Corporation of America, NeoGenomics, Psychemedics and Qiagen in the following table:
Quest Diagnostics competitorsOne check before investing in any stock is to have a look a list of its competitors, in this case for Quest Diagnostics. We picked 5 companies as Quest Diagnostics competitors as they are in the same industry or have similar market objectives.
- Enzo Biochem (ENZ)
- Laboratory Corporation of America (LH)
- NeoGenomics (NEO)
- Psychemedics (PMD)
- Qiagen (QGEN)
Latest DGX stock news
- Seeking AlphaDiagnosing Quest DiagnosticsMarch 15, 2019